<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745210</url>
  </required_header>
  <id_info>
    <org_study_id>59093</org_study_id>
    <nct_id>NCT02745210</nct_id>
  </id_info>
  <brief_title>Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy.</brief_title>
  <official_title>Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the decline in fatal traumatic brain injury (TBI) incidence in recent years, TBI&#xD;
      morbidity remains a public health challenge and is the leading cause of disability in the&#xD;
      United States. Detailed knowledge of the metabolic alterations following TBI will provide a&#xD;
      significant advancement to our understanding of the hypometabolic response to TBI, which is&#xD;
      key information for the future development and testing of novel therapeutic interventions&#xD;
      that by-pass or compensate for the metabolic dysfunction.&#xD;
&#xD;
      The goal of this study is to determine the clinical utility of in vivo 13C MRS to identify&#xD;
      specific metabolic alterations following TBI. We hypothesize that following TBI, metabolic&#xD;
      pathways are altered causing an incomplete oxidative of glucose in neurons and astrocytes&#xD;
      resulting in a decrease in cerebral metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the decline in fatal traumatic brain injury (TBI) incidence in recent years, TBI&#xD;
      morbidity remains a public health challenge and is the leading cause of disability in the&#xD;
      United States To combat these effects, new research is needed to identify mechanisms of&#xD;
      injury that will lead to potential targets for therapeutic interventions that improve&#xD;
      neurological outcome. One promising area of research is the cerebral metabolic dysfunction&#xD;
      following TBI. Studies of post-traumatic cerebral metabolism have shown that cerebral&#xD;
      metabolic rate of glucose (CMRglc) decreases for a period of days, weeks or months after&#xD;
      injury with the duration and degree of hypometabolism correlating to level of consciousness&#xD;
      and a strong predictor of long-term neurological outcome. However, specific changes in&#xD;
      intermediary carbohydrate metabolic pathways have not yet been identified. In addition, the&#xD;
      role of astrocyte metabolism in the post-injury metabolism has not been studied. This study&#xD;
      uses in vivo 13C magnetic resonance spectroscopy (MRS) at 3 Tesla, a novel method in the&#xD;
      clinical study of TBI, to non-invasively study the metabolic fate and flux of glucose&#xD;
      (metabolized in both neurons and astrocytes) and acetate (metabolized in astrocytes) through&#xD;
      metabolic pathways during the hypometabolic period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The acquisition sequence was incompatible with MRI hardware&#xD;
  </why_stopped>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of 13C Enriched Cerebral Metabolites</measure>
    <time_frame>5 years</time_frame>
    <description>Direct detection, localized in vivo 13C MRS will be used to measure the 13C enrichment of glutamate and glutamine following an infusion of 30% isotopically enriched [1-13C] glucose and [1, 2-13C2] acetate.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C Magnetic resonance (MR) spectroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>13C magnetic resonance spectroscopy</intervention_name>
    <description>acquisition of 13C MR spectroscopy in the brain</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>13C MRS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects will be at least 18 years of age without gender or ethnic restrictions.&#xD;
&#xD;
          2. Severe accidental TBI defined as the lowest post-resuscitation GCS &lt; 8 prior to&#xD;
             administration of sedatives or paralytics.&#xD;
&#xD;
          3. Eligibility for MRI per routine screening checklist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of neurosurgical intervention, excluding the placement of ventriculostomy&#xD;
             shunt&#xD;
&#xD;
          2. History of a prior known brain injury with associated loss of consciousness.&#xD;
&#xD;
          3. History of a known neurological disorder prior to qualifying injury.&#xD;
&#xD;
          4. History of psychiatric disorder.&#xD;
&#xD;
          5. History of diabetes or current unstable serum glucose level.&#xD;
&#xD;
          6. Renal insufficiency or known history of kidney disease.&#xD;
&#xD;
          7. Known contraindication to MRI such as, pacemaker, pregnancy, and/or other non-MR&#xD;
             compatible implanted device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <results_first_submitted>October 1, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Brenda Bartnik Olson, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02745210/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from medical, surgical, or neurological services of LLUMC. Non-injured participants were recruited from MRI staff, Loma Linda University student or Resident populations</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Traumatic Brain Injury</title>
          <description>Participants with TBI undergoing 13C Magnetic resonance (MR) spectroscopy.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>control (non-injured) participants undergoing 13C Magnetic resonance (MR) spectroscopy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No traumatic brain injury participants were recruited</population>
      <group_list>
        <group group_id="B1">
          <title>Traumatic Brain Injury</title>
          <description>Participants with TBI undergoing 13C Magnetic resonance (MR) spectroscopy.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>control (non-injured) participants undergoing 13C Magnetic resonance (MR) spectroscopy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="33" spread="7.71"/>
                    <measurement group_id="B3" value="33" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection of 13C Enriched Cerebral Metabolites</title>
        <description>Direct detection, localized in vivo 13C MRS will be used to measure the 13C enrichment of glutamate and glutamine following an infusion of 30% isotopically enriched [1-13C] glucose and [1, 2-13C2] acetate.</description>
        <time_frame>5 years</time_frame>
        <population>We were not successful in out attempt to collect localized in vivo 13C MRS thus there were no metabolite enrichments to measure and include in the measure data table.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>13C Magnetic resonance (MR) spectroscopy.&#xD;
13C magnetic resonance spectroscopy: acquisition of 13C MR spectroscopy in the brain</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of 13C Enriched Cerebral Metabolites</title>
          <description>Direct detection, localized in vivo 13C MRS will be used to measure the 13C enrichment of glutamate and glutamine following an infusion of 30% isotopically enriched [1-13C] glucose and [1, 2-13C2] acetate.</description>
          <population>We were not successful in out attempt to collect localized in vivo 13C MRS thus there were no metabolite enrichments to measure and include in the measure data table.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>Adverse event collection was based on self-reporting by participants</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>13C Magnetic resonance (MR) spectroscopy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brenda Bartnik Olson</name_or_title>
      <organization>Loma LInda University Medical Center</organization>
      <phone>1-909-558-4000 ext 85216</phone>
      <email>BBartnik@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

